Cellectis S.A. (CLLS) has been beaten down lately with too much selling pressure. While the stock has lost 28% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator tha ...

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) --  Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a scientific article in Nature Communications, unveiling a non-viral gene therapy approach for sickle cell disease. Sickle cell disease (SCD) is one of the most common inherited diseases worldwide. SCD is caused by a single point muta ...

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a scientific article in Nature Communications, unveiling a non-viral gene therapy approach for sickle cell disease. Sickle cell disease (SCD) is one of the most common inherited diseases worldwide. SCD is caused by a single point muta ...

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that the European Commission (EC) has granted an Orphan Drug Designation (ODD) to its product candidate UCART22, for the treatment of Acute Lymphoblastic Leukemia (ALL). UCART22 is an allogeneic CAR T-cell product candidate targeting CD22 and evaluated in ...

财务数据和关键指标变化 - 公司现金、现金等价物、受限现金和定期存款于2024年3月31日为1.43亿美元,较2023年12月31日的1.56亿美元减少1300万美元 [29] - 公司认为其现金和现金等价物将足以为其运营提供资金至2026年,即至少12个月 [31] - 2024年第一季度归属于Cellectis股东的合并净收益为560万美元,每股0.08美元收益,而2023年同期为3010万美元亏损,每股0.58美元亏损 [32] - 2024年第一季度归属于Cellectis股东的经调整合并净收益为650万美元,每股0.09美元收益,而2023年同期为2810万美元亏损,每股0.55美元亏损 [34] 各条业务线数据和关键指标变化 - BALLI-01试验中,UCART22-P2制造的细胞比UCART22-P1更有效 [19][20][21][22] - NatHaLi-01试验中,UCART20x22在3例患者中均有反应,包括1例部分代谢反应和2例完全代谢反应 [23][24][25] - AMELI-01试验正在继续推进,正在以氟达拉滨、环磷酰胺和阿仑单抗淋巴细胞清除的2剂方案给患者输注 [26] 各个市场数据和关键指标变化 - 公司在美国和欧洲(法国和西班牙)开设了NatHaLi-01试验的临床试验点 [52] 公司战略和发展方向及行业竞争 - 公司将继续专注于推进自有的BALLI-01、NatHaLi-01和AMELI-01临床试验,同时与阿斯利康合作开发下一代基因编辑细胞和基因疗法 [13] - 公司相信基因编辑细胞和基因疗法将在多个治疗领域革新医疗,未来将成为分子医学的重要组成部分 [39] - 阿斯利康现持有公司约44%的股本和30%的表决权,并已委派两名董事加入公司董事会 [12] 管理层对经营环境和未来前景的评论 - 公司对与阿斯利康的战略合作和投资感到兴奋,相信这将有助于开发下一代细胞和基因疗法 [8][38][39] - 公司有信心推进自有的三项临床试验,并继续开发前期管线 [13][38][39] 其他重要信息 - 公司任命Arthur Stril为临时首席财务官,接替Bing Wang [14][15][16] - 阿斯利康于2024年5月3日追加投资1.4亿美元,持有公司约44%的股本和30%的表决权 [9][10][11][12] 问答环节重要的提问和回答 问题1 **Gena Wang 提问** - 阿斯利康合作对公司战略有何影响?公司制造能力是否可供阿斯利康使用?未来数据更新时间表如何? [42][43][44][47] **Arthur Stril 和 Mark Frattini 回答** - 自有管线战略未变,仍在大力推进UCART22、UCART20x22和UCART123 [43][44][47] - 阿斯利康可能会利用公司的制造能力,这是其感兴趣的一个原因 [44][45] - 预计2024年底将公布UCART22和UCART20x22的数据更新 [47][48] 问题2 **Dev Prasad 提问** - UCART20x22目前有多少活跃临床试验点?是否能在2024年底确定推荐剂量? [51] **Mark Frattini 回答** - 在美国和欧洲(法国和西班牙)都有活跃的临床试验点 [52] - 计划在2024年底前完成剂量递增阶段,届时将确定推荐剂量 [52][53] 问题3 **Salveen Richter 提问** - 2024年各项目的数据更新时间表和预期 [55] **Mark Frattini 回答** - UCART22和UCART20x22将在2024年底完成剂量递增阶段并公布数据 [57][58] - UCART123正在以2剂方案给患者输注,将在有足够数据时公布 [58]

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 28, 2024 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice convening the annual general meeting stating the detailed agenda and modalities of participation in the meeting is avail ...

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 28, 2024 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice convening the annual general meeting stating the detailed agenda and modalities of participatio ...

• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 • Conference call and webcast scheduled for tomorrow, May 29, 2024 at 8:00AM ET / 2:00PM CET NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapie ...

as Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three-month periods ended March 31, 2024, included herein, have been prepared in accordance with International Accounting Standard 34 (“IAS 34”)– Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements are presented in U.S. dollars. All references in this interim report to “$” and “U.S. dollars” mean U.S. dollars and all references t ...

NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2024 ending March 31, 2024 on Tuesday, May 28, 2024 after the close of the US market. The publication will be followed by an investor conference call and webcast on Wednesday, May 29, 2024 at 8:00 AM ET / 2:00 PM CET. The ...